Sonoclot Signature Analysis in Patients with Liver Disease and Its Correlation with Conventional Coagulation Studies

Table 2

Comparison between sonoclot parameters in different groups.

Group		G1	G2	G3	G4	Control
SONACT	Mean ± SD (s)	176.31±51.41	146.14±41.76	130.09±31.23	152.44±13.22	137±24.46
	Median (s)	164	147	140	148	143.5
	𝑊𝐶	88*	27*	22*	23*	—
CR	Mean ± SD (u/min)	29.41±11.31	42.5±17.64	44.54±10.44	34.88±11.54	31.6±7.63
	Median (u/min)	30	44.5	48	30	44
	𝑊𝐶	50*	59*	56*	11*	—
PF	Mean ± SD	1.54±1.08	2.29±1.31	2.97±0.84	1.36±1.13	2.53±0.76
	Median	1.5	2.7	3.0	1.4	2.45
	𝑊𝐶	98*	07¶	45*	31*	—
TP	Mean ± SD (min)	20.5±10.2	11.5±7.6	9.5±10.4	15.3±11.9	11.8±2.8
	Median	17	9.5	6	10	11.5
	𝑊𝐶	116*	18¶	44*	11*	—
PA	Mean ± SD (units)	75.31±25.13	91.07±21.94	97.91±8.61	71.94±24.99	95.7±7.48
	Median	80	95	100	75	93.5
	𝑊𝐶	88*	05¶	32*	33*	—
	𝑊𝑇	29	21	10	05	—

G1: group 1 (decompensated cirrhosis), G2: group 2 (noncirrhotic liver disease), G3: group 3 (cirrhotic HCC), G4: group 4 (ACLF).
SONACT: sonoclot activated clotting time, CR: clot rate, PF: platelet function, TP: time to peak, PA: peak amplitude.
SD: standard deviation.
𝑊_𝐶: calculated Wilcoxon test statistic (patient groups versus controls), 𝑊_𝑇: tabulated Wilcoxon critical value of alpha = 0.05 (𝑊_𝑐 > 𝑊_𝑇 is considered to be statistically significant).
*Significantly different values as compared to control group.
¶Values are not significantly different as compared to controls.